Navigation Links
Chicken Anti-Corticoliberin Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.

ProductsChicken Anti-Corticoliberin Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Company GenWay Biotech, Inc.
Item Chicken Anti-Corticoliberin Polyclonal Antibody, Unconjugated
Price $185.00
Description Corticoliberin
Info GenWay Biotech, Inc.GenWay Biotech, Inc.
6777 Nancy Ridge Drive
San Diego, CA 92121
Customer Service: 858-458-0866
Fax Number: 858-458-0833
Web Site: http://www.genwaybio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Chicken Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
2. Chicken Anti-UCK2 Polyclonal Antibody, Unconjugated from Abcam
3. Chicken Anti-HADHSC Azide Free Polyclonal Antibody, Unconjugated from Abcam
4. Rabbit Anti-Chicken IgY, IgG F(ab)2 fragment Antibody, Rhodamine Conjugated from Biomeda Corporation
5. Rabbit Anti-Chicken IgY, IgG F(ab)2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
6. Chicken Anti-Human Stomatin-like 2 (STOML2) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
7. Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
8. Chicken Anti-Polymerase (RNA) II (DNA directed) polypeptide L Antibody, Unconjugated from CHEMICON
9. Chicken Anti-Rab GDP dissociation inhibitor beta Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
10. Chicken Anti-Human Complement Component C4c Antibody, Unconjugated from CEDARLANE Laboratories Limited
11. Chicken Anti-HSPBP1 Polyclonal Antibody, Unconjugated from ProSci, Inc
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products:
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... October 22, 2014 WriteResult, LLC ... – has been working with a team of researchers ... Haven Farms Community Farming Collaborative to provide electronic questionnaire ... The study, which started in May, aims to ... provides participants weekly exposure to and participation in urban ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4